The standard of care for BRAF-mutated melanoma is now the combination of BRAF inhibitors and MEK inhibitors [7,8], as there is considerable high-quality evidence from randomized comparative studies that this approach prolongs progression-free survival (PFS) and overall survival (OS) compared with BRAF inhibitor monotherapy [177,178,179,180,181,182,183,184,185,186,187]. The gene discussed is BRAF; the disease is melanoma.